METIS Phase 3 trial shows Tumor Treating Fields therapy improves time to intracranial progression for adults with 1-10 brain metastases from non-small cell lung cancer.
Zai Lab partner Novocure reports METIS Phase 3 clinical trial met primary endpoint with Tumor Treating Fields (TTFields) therapy, showing a statistically significant improvement in time to intracranial progression (21.9 months vs. 11.3 months) for adult patients with 1-10 brain metastases from non-small cell lung cancer following stereotactic radiosurgery. Median TTFields therapy treatment duration was 16 weeks, and its usage was 67%. Consistent with previous studies, TTFields therapy was well-tolerated with sustained quality of life and neurocognitive function.
March 27, 2024
4 Articles